Zydus Cadila gets approval from DCGI for phase-III clinical trials

Zydus Cadila Pharmaceuticals has announced that the company has received an approval from the Drugs Controller General of India -DCGI to begin the phase-III clinical trials with its biological therapy Pegylated Interferon alpha-2b (PegiHep) in Covid-19 patients.PegiHep is an approved drug and is being re-purposed for the treatment of Covid-19. The trials will be conducted …

Zydus Cadila gets approval from DCGI for phase-III clinical trials Read More »